Suppr超能文献

乳腺血管肉瘤监测研究:英国全国范围内对乳腺和胸壁血管肉瘤的管理和结局的审计。

Breast Angiosarcoma Surveillance Study: UK national audit of management and outcomes of angiosarcoma of the breast and chest wall.

机构信息

Department of Breast Surgery, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.

Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.

出版信息

Br J Surg. 2021 Apr 30;108(4):388-394. doi: 10.1093/bjs/znaa128.

Abstract

BACKGROUND

Breast angiosarcomas are rare tumours of vascular origin. Secondary angiosarcoma occurs following radiotherapy for breast cancer. Angiosarcomas have high recurrence and poor survival rates. This is concerning owing to the increasing use of adjuvant radiotherapy for the treatment of invasive breast cancer and ductal cancer in situ (DCIS), which could explain the rising incidence of angiosarcoma. Outcome data are limited and provide a poor evidence base for treatment. This paper presents a national, trainee-led, retrospective, multicentre study of a large angiosarcoma cohort.

METHODS

Data for patients with a diagnosis of breast/chest wall angiosarcoma between 2000 and 2015 were collected retrospectively from 15 centres.

RESULTS

The cohort included 183 patients with 34 primary and 149 secondary angiosarcomas. Median latency from breast cancer to secondary angiosarcoma was 6 years. Only 78.9 per cent of patients were discussed at a sarcoma multidisciplinary team meeting. Rates of recurrence were high with 14 of 28 (50 per cent ) recurrences in patients with primary and 80 of 124 (64.5 per cent ) in those with secondary angiosarcoma at 5 years. Many patients had multiple recurrences: total of 94 recurrences in 162 patients (58.0 per cent). Median survival was 5 (range 0-16) years for patients with primary and 5 (0-15) years for those with secondary angiosarcoma. Development of secondary angiosarcoma had a negative impact on predicted breast cancer survival, with a median 10-year PREDICT prognostic rate of 69.6 per cent, compared with 54.0 per cent in the observed cohort.

CONCLUSION

A detrimental impact of secondary angiosarcoma on breast cancer survival has been demonstrated. Although not statistically significant, almost all excess deaths were attributable to angiosarcoma. The increased use of adjuvant radiotherapy to treat low-risk breast cancer and DCIS is a cause for concern and warrants further study.

摘要

背景

乳腺血管肉瘤是一种罕见的血管来源肿瘤。继发性血管肉瘤继发于乳腺癌放疗后。血管肉瘤的复发率和生存率都很高。这令人担忧,因为辅助放疗治疗浸润性乳腺癌和导管原位癌(DCIS)的应用越来越多,这可能是血管肉瘤发病率上升的原因。目前的预后数据有限,为治疗提供的证据基础较差。本文介绍了一项由培训生主导的全国性回顾性多中心大型血管肉瘤队列研究。

方法

从 15 个中心回顾性收集了 2000 年至 2015 年期间诊断为乳腺/胸壁血管肉瘤的患者数据。

结果

该队列包括 183 例患者,其中 34 例为原发性,149 例为继发性血管肉瘤。从乳腺癌到继发性血管肉瘤的潜伏期中位数为 6 年。只有 78.9%的患者在肉瘤多学科治疗小组会议上进行了讨论。复发率很高,原发性血管肉瘤患者中有 14 例(50%)在 5 年内复发,继发性血管肉瘤患者中有 80 例(64.5%)在 5 年内复发。许多患者有多次复发:在 162 例患者中有 94 例复发(58.0%)。原发性血管肉瘤患者的中位生存时间为 5 年(范围 0-16 年),继发性血管肉瘤患者为 5 年(范围 0-15 年)。继发性血管肉瘤的发生对预测乳腺癌的生存有负面影响,中位 10 年 PREDICT 预后率为 69.6%,而观察队列为 54.0%。

结论

已经证明继发性血管肉瘤对乳腺癌生存有不利影响。尽管没有统计学意义,但几乎所有的超额死亡都归因于血管肉瘤。辅助放疗治疗低危乳腺癌和 DCIS 的应用越来越多,令人担忧,需要进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验